Biotech Investment Paradigm

In the next few days, the FDA is expected to announce whether or not Spectrum Pharmaceuticals’ (NASDAQ: SPPI) Zevalin should still require a pre-treatment screen, termed the “bioscan”, possibly removing what management believes is the last hurdle to a dramatic increase in Zevalin prescriptions. Zevalin is an antibody attached to Yttrium-90, a radioactive isotope that [...]

  DUSA Pharmaceuticals, Inc. (DUSA) – based in Wilmington, MA is a dermatology company engaged in the development and commercialization of Levulan photodynamic therapy (PDT).  Utilizing their proprietary Kerastick 20% Topical Solution with PDT and the BLU-U brand light source for the treatment of non-hyperkeratotic actinic keratoses (AKs) of the face or scalp, the company [...]

Last week, Inhibitex (NASDAQ: INHX) updated guidance on its program in HCV with positive top-line data from the first cohort of a trial of INX-189 in treatment-naïve patients infected with genotype 1 HCV. Patients in this arm received 200 mg of Inhibitex’s nucleotide polymerase inhibitor INX-189 once daily and saw a median reduction in viral [...]